93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

Autor:	G. Gebhart, M. Keyaerts, T. Guiot, P. Flamen, M. Ruiz Borrego, A. Stradella, B. Bermejo De Las Heras, S. Escriva de Romani, L. Calvo-Martinez, N. Ribelles Entrena, N. Martinez, C.R. Albacar Miro, M.A. Colleoni, M. Atienza de Frutos, M. Sampayo-Cordero, J. Cortés, J.M. Perez Garcia, A. Llombart Cussac
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S166
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2022.03.109
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7828c4c39cbd8f2b302f43755fa4110d https://doi.org/10.1016/j.annonc.2022.03.109 Zobrazit plný text záznamu